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Abstract Eribulin mesylate, a novel non-taxane micro-
tubule dynamics inhibitor, is approved for treatment of
metastatic breast cancer (MBC) in patients who have pre-
viously received at least 2 chemotherapeutic regimens for
MBC that should have included an anthracycline and a
taxane in the adjuvant or metastatic setting. This phase 2
study evaluated efficacy and safety of eribulin as first-line
therapy for human epidermal growth factor receptor
2-negative (HER2-negative) MBC. Patients with measur-
able HER2-negative locally recurrent breast cancer or
MBC with C12 months since prior neoadjuvant or adju-
vant (neo/adjuvant) chemotherapy received eribulin
mesylate 1.4 mg/m2 IV on days 1 and 8 of each 3-week
cycle. Endpoints included objective response rate (ORR)
per RECIST v1.1 (primary), safety, progression-free sur-
vival (PFS), clinical benefit rate (ORR ? stable disease
C6 months; CBR), and duration of response (DOR). Fifty-
six patients were enrolled and received eribulin; 38 (68 %)
had prior neo/adjuvant therapy, including 33 who had
anthracycline and/or taxane-containing chemotherapy; 41
(73 %) had estrogen receptor-positive disease, and 12
(21 %) had estrogen receptor-negative, progesterone
receptor-negative, and HER2-negative (triple-negative)
disease. Patients received a median of 7 cycles (range
1–43); 6 (11 %) received treatment for C12 months. ORR
was 29 % (95 % CI 17.3–42.2), CBR was 52 %, and
median DOR was 5.8 months. Median PFS was
6.8 months. Thirty-six patients (64 %) had grade 3/4
treatment-related adverse events; most common were
neutropenia (50 %), leukopenia (21 %), and peripheral
neuropathy (21 %). These results demonstrate that eribulin
has substantial antitumor activity as first-line treatment for
HER2-negative MBC with acceptable safety.
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Introduction
Metastatic breast cancer (MBC) is incurable, with a 5-year
survival of approximately 23 % [1]. Selection of therapy
for MBC or locally recurrent disease is guided by several
factors, including biology, clinical presentation, as well as
patients’ choices, hormone receptor (estrogen receptor and
progesterone receptor) expression and sensitivity, human
epidermal growth factor receptor 2 (HER2) receptor
expression, location and burden of metastases, disease-free
interval from diagnosis of early breast cancer and neo/
adjuvant therapy, and prior treatment history [2]. HER2-
negative breast cancer is more common and generally
associated with increased survival relative to HER2-posi-
tive (HER2?) breast cancer; however, differences in
estrogen receptor and progesterone receptor expression are
also important factors that affect survival [3–5].
According to recent NCCN Guidelines, preferred single
agents for MBC include anthracycline, taxane, antimetab-
olites (capecitabine and gemcitabine), and other microtu-
bule-disrupting agents (including vinorelbine and eribulin)
[2]. Current guidelines do not specify a preferred regimen
for HER2-negative MBC. Cytotoxic agents with antitumor
efficacy that is not cross resistant with anthracyclines and
taxanes are of particular clinical utility in the treatment of
MBC.
Eribulin mesylate is a non-taxane inhibitor of microtu-
bule dynamics belonging to the halichondrin class of
antineoplastic drugs [6–8]. Eribulin is a structurally mod-
ified synthetic analog of halichondrin B, a natural product
isolated from the marine sponge Halichondria okadai, with
a novel mode of action distinct from those of other tubulin-
targeting agents [6–8]. Eribulin has demonstrated antitu-
mor activity and a survival benefit in women with MBC
who previously received at least 2 chemotherapeutic regi-
mens (including an anthracycline and a taxane) [9–12] and
is approved by the United States (US) Food and Drug
Administration for this use [13]. The approval was based
on the results from the phase 3 EMBRACE study, which
demonstrated that single-agent eribulin significantly
improved overall survival (OS) in women with MBC
compared with treatment of the physician’s choice [12].
Notably, most women in the phase 2 studies {86 %
(89/103) [9], 83 % (224/269) [10], 89 % (71/80) [11]} and
the EMBRACE study {74 % (565/762) [12]} had HER2-
negative MBC. In a separate study—a prespecified
exploratory subgroup analysis of a phase 3, randomized,
open-label study (the overall study failed to meet its pri-
mary endpoint)—median OS was improved in patients
receiving eribulin compared with capecitabine among
patients with HER2-negative (15.9 vs 13.5 months; hazard
ratio [HR] 0.84 [95 % CI 0.72–0.98]), estrogen receptor-
negative (14.4 vs 10.5 months; HR 0.78 [95 % CI
0.64–0.96]), and triple-negative (14.4 vs 9.4 months; HR
0.70 [95 % CI 0.55–0.91]) breast cancer [14].
In view of the overall tolerability and non-cross-resistant
antitumor activity in previous studies, primarily in pre-
treated MBC, including women with HER2-negative dis-
ease, eribulin may provide a treatment advantage when
given earlier in the course of therapy. The current non-
randomized phase 2 study was designed to explore the
antitumor activity and safety of eribulin mesylate as first-
line therapy in patients with locally recurrent or metastatic
HER2-negative breast cancer.
Methods
This multicenter, phase 2, open-label, single-arm proof-of-
concept study recruited patients with HER2-negative
locally recurrent breast cancer or MBC not previously
treated with chemotherapy in this setting. Patients were
enrolled and treated at 25 sites in the US. The study was
conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice guidelines, the protocol was
approved by local institutional review boards/ethics com-
mittees, and patients provided written informed consent
before enrollment.
The primary objective was to evaluate the objective
response rate (ORR, comprising complete response [CR] or
partial response [PR]), as defined according to Response
Evaluation Criteria in Solid Tumors version 1.1 (RECIST
v1.1). Secondary objectives included evaluations of safety
and tolerability, time to response (TTR), duration of
response (DOR), and progression-free survival (PFS).
Patients
Key inclusion criteria were as follows: Women aged
C18 years with histologically or cytologically confirmed
locally recurrent breast cancer or MBC; measureable dis-
ease according to RECIST v1.1; HER2-negative disease as
determined by immunohistochemical staining (0 or 1?) or
by fluorescence in situ hybridization (FISH) (subjects with
a HER2:FISH ratio of 1.8:2.2 were eligible); life expec-
tancy C24 weeks; Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2; at least 12 months
since prior neoadjuvant or adjuvant (neo/adjuvant)
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chemotherapy ended; at least 2 weeks since prior radio-
therapy or endocrine therapy was finished or discontinued,
with complete recovery from the effects of these inter-
ventions; and adequate renal, bone marrow, and liver
functions.
Key exclusion criteria were as follows: prior chemo-
therapy, biologic therapy, or investigational therapy for
locally recurrent breast cancer or MBC (prior endocrine
therapy was permitted); prior malignancy (other than car-
cinoma in situ of the cervix or non-melanoma skin cancer)
within 5 years; prior exposure to[360 mg/m2 doxorubicin
or [720 mg/m2 epirubicin; inflammatory breast cancer;
preexisting neuropathy of grade [2 (according to the
National Cancer Institute [NCI] Common Terminology
Criteria for Adverse Events [CTCAE] version 4.0).
Treatment
Eribulin mesylate (1.4 mg/m2 [equivalent to 1.23 mg/m2
eribulin]) was administered as a 2- to 5-min intravenous
(IV) infusion on Days 1 and 8 of a 21-day cycle (pre-
medication to prevent hypersensitivity was not required,
antiemetics were allowed as per institutional guidelines).
Dose reductions were implemented as follows:
(1) The dose was reduced to 1.1 mg/m2 if one of the
following occurred during the previous cycle:
(a) absolute neutrophil count (ANC)\500 cells/mm3
for [7 days despite use of growth factor,
recovered to grade B2;
(b) ANC \1,000 cells/mm3 with fever or infec-
tion despite use of growth factor recovered to
grade B2;
(c) any grade 3 or 4 non-hematologic toxicity that
returned to grade B2 within 7 days.
(2) The dose was further reduced to 0.7 mg/m2 if there
was a recurrence of grade 3 or 4 toxicity despite dose
reduction to 1.1 mg/m2.
Concomitant treatments
Concomitant medication that did not interfere with the
evaluation of eribulin could be given at the discretion of
the investigator, including antiemetics, antidiarrheal ther-
apy, corticosteroids, and antihistamines. Granulocyte col-
ony-stimulating factor, granulocyte–macrophage colony-
stimulating factor, and erythropoietin were allowed
according to American Society of Clinical Oncology
guidelines and standard practice, including prophylactic
use of growth factors. Patients treated with bisphospho-
nates or denosumab at study entry could continue treat-
ment. Other antitumor therapies were not allowed.
Assessments
Efficacy
Baseline tumor assessments were performed within
28 days before the first infusion of study treatment by
radiographic evaluation (computerized tomography [CT] or
magnetic resonance imaging [MRI] scans) of the chest,
abdomen, pelvis, brain, and any other areas of known or
suspected disease, along with clinical assessment of skin
lesions, if applicable. A bone scan was also performed
within 6 weeks before the first study treatment. Subsequent
radiographic tumor imaging was performed every 6 weeks
for the first 6 cycles and then every 12 weeks thereafter.
Postscreening bone scans were performed only if clinically
indicated. Tumor assessments were analyzed based on
RECIST v1.1 and classified as CR, PR, stable disease,
progressive disease (PD), or not evaluable (NE). Tumor
response was confirmed by a second examination per-
formed at least 4 weeks after the criteria for response were
met.
The primary efficacy variable was ORR, defined as the
proportion of patients who achieved a CR plus those who
achieved a PR. Clinical benefit rate (CBR) was defined as
the proportion of patients who achieved a CR plus those
who achieved a PR, plus those with stable disease for
C6 months. TTR was measured from start of treatment
until the earliest date a CR or PR was documented. DOR
was measured from the first documentation of CR/PR until
disease progression or death from any cause. PFS was
measured from the start of treatment until disease pro-
gression or death from any cause.
Safety/tolerability
Safety evaluations at baseline and subsequent visits inclu-
ded adverse events (AEs), clinical laboratory tests, physical
examination, vital signs, and electrocardiogram assess-
ments. AEs were graded using the NCI CTCAE v4 and
coded using Medical Dictionary for Regulatory Activities
(MedDRA) version 15.0 or above. Serious AEs were
defined as events that resulted in death, were life threat-
ening, required (or prolonged) hospitalization, resulted in
persistent disability, or required intervention to prevent any
of these outcomes.
Statistical analysis
A planned enrollment of at least 52 patients was chosen to
ensure a standard error (SE) of the response rate B7 % and
a half-width of the 95 % confidence interval (CI) B14 %.
The full analysis set, which included all patients who
received C1 dose of eribulin, was the primary population
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for efficacy evaluations. The safety analysis set included all
patients who received C1 dose of eribulin and had at least 1
postbaseline safety evaluation. ORR was calculated with
corresponding 2-sided, exact binomial 95 % CIs. Second-
ary efficacy variables were analyzed using Kaplan–Meier
methods, with corresponding median and 95 % CI.
Results
Patients
Of 68 patients screened, 56 patients enrolled and received
at least 1 dose of eribulin (safety population/full analysis
set) (Fig. 1). Patients had a median age of 56 years (range
31–85 years); 32 (57 %) had an ECOG performance status
of 0; 41 (73 %) had estrogen receptor-positive disease, and
12 (21 %) had TN disease (Table 1). A total of 38 patients
(68 %) had received neo/adjuvant therapy. Twenty-seven
patients (48 %) had received prior anthracyclines (26/56
[46 %] in the neo/adjuvant setting), and 26 patients (46 %)
had received prior taxanes (25/56 [45 %] in the neo/adju-
vant setting).
Exposure
Thirty-two patients (57 %) completed at least 6 cycles of
treatment. The median number of cycles delivered was 7
(range 1–43); the median duration of exposure was
4.5 months, and 6 patients (11 %) received treatment for
12 months or longer. Twenty patients (35.7 %) had C1 dose
reduction; for any reason; the median time to dose reduction
was 9.1 weeks (range 2.7–43.1). Twenty-seven patients
(48.2 %) had C1 dose delay; for any reason; the duration of
dose delays was typically\2 weeks (18 of 27 patients), with
a median of 50 days (range 1–217). The median relative dose
intensity was 95 % (range 47.9–102.5). Twenty-two patients
(39.3 %) received growth factors.
Efficacy
The ORR was 28.6 % (16/56 pts) (95 % CI 17.3–42.2); the



















Fig. 1 Patient flow diagram









Black/African American 12 (21)
Asian 1 (2)
Other 1 (2)




Stage IV breast cancer, n (%) 56 (100)
Interval from initial diagnosis of breast cancer (in
years), median (range)
2.7 (0–31.3)
Interval from initial diagnosis to MBC, n (%)
\3 months 17 (30)
C3 months 39 (70)
Receptor status, n (%)
Estrogen receptor-positive or progesterone
receptor-positive
44 (79)
Estrogen receptor-negative and progesterone
receptor-negative
12 (21)
Site of metastases, n (%)
Liver 25 (45)
Lung 22 (39)
Preexisting neuropathy, n (%) 9 (16)
Prior chemotherapy (breast), n (%) 36 (64)
Anthracycline 27 (48)
Taxane 26 (46)
Interval following completion of neo/adjuvant therapy, n (%)
\2 years 10 (18)
C2 years 28 (50)
Prior endocrine therapy, n (%) 26 (46)
ECOG Eastern Cooperative Oncology Group, MBC metastatic breast
cancer, SD standard deviation, TN triple negative
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and overall CBR was 51.8 % (Table 2). Among the 16
patients with an objective response, the median TTR was
1.4 months (95 % CI 1.2–2.7), and median DOR was
5.8 months (95 % CI 4.7–10.6) (Table 2). Among all
patients, the median PFS was 6.8 months (95 % CI
4.4–7.6) (Fig. 2). The majority of patients (43/56 [76.8 %])
experienced a decrease in the sum of target lesion diame-
ters from baseline to postbaseline nadir (Fig. 3).
Outcomes among patients with estrogen receptor-posi-
tive MBC (n = 41) were an ORR of 34.1 %, a stable
disease rate of 51.2 %, a PD rate of 12.2 %, and a CBR of
63.4 % (Table 2). DOR was 7.4 months, and PFS was
7.4 months. In patients with TN MBC (n = 12), the ORR
was 16.7 %, the stable disease rate was 33.3 %, the PD rate
was 41.7 %, the CBR was 25.0 %, and median PFS was
3.4 months.
The ORR among patients who had received neo/adju-
vant treatment with anthracyclines and/or taxanes (A/T)
was 27.3 % (9/33)—and the CBR was 45.5 % (15/33)—
findings that were similar to the overall study population.
There was no difference in PFS among patients who had
received prior A/T (n = 33) versus those who had neo/
adjuvant treatment without A/T (n = 6): median PFS was
5.9 and 5.7 months, respectively. The ORRs for additional
subgroups are shown in Fig. 4.
Safety
All 56 patients experienced a treatment-related AE
(TRAE); 36 patients (64.3 %) experienced a grade 3/4
TRAE according to CTCAE, the most common of which
were neutropenia (50 % [any grade: 71 %]), peripheral
neuropathy (20 % [any grade: 57 %]), and leukopenia
(21 % [any grade: 34 %]) (Table 3). Fatigue was reported
for 36 patients (64 % [grade 3/4: 2 %]) and febrile neu-
tropenia for 4 patients (7 %; all grade 3/4).
Treatment-related serious AEs occurred in 5 (9 %)
patients: febrile neutropenia occurred in 3 (5.4 %) patients,
neutropenia in 3 (5.4 %), and leukopenia in 1 (1.8 %).
Growth factors were administered to 22 (39.3 %) patients,
with a median start of 2.6 weeks (18 days) from the first
dose of study drug (range 1.1–45.6). Among the 22 patients
who received growth factors, 10 had received both pro-
phylactically and following an adverse event; 6 had pro-


















0 4 8 12 16 20
Survival Time (Months)
28 3224
Median time (months): 6.8 (4.44, 7.59)
1st Quartile (months): 2.6 (1.28, 4.44)
3rd Quartile (months): 11.9 (7.39, 14.72)
Fig. 2 Kaplan–Meier plot of progression-free survival
Table 2 Efficacy outcomes
Best tumor response, n (%) unless otherwise stated All (N = 56) Estrogen receptor-positive (n = 41) Triple negative (n = 12)
ORR 16 (28.6) 14 (34.1) 2 (16.7)
95 % CI 17.3–42.2 20.1–50.6 2.1–48.4
CR 0 0 0
PR 16 (28.6) 14 (34.1) 2 (16.7)
Stable disease 26 (46.4) 21 (51.2) 4 (33.3)
PD 11 (19.6) 5 (12.2) 5 (41.7)
NE/unknown 3 (5.4) 1 (2.4) 1 (8.3)
CBR 29 (51.8) 26 (63.4) 3 (25.0)
95 % CI 38.0–65.3 46.9–77.9 5.5–57.2
Other secondary efficacy outcomes n Median months (95 % CI) n Median months (95 % CI) n Median months (95 % CI)
PFS 56 6.8 (4.44–7.59) 41 7.4 (6.1–11.9) 12 3.4 (1.2–6.8)
TTR 16 1.4 (1.22–2.66) 14 2.0 (1.3–2.7) 2 NE
DOR 16 5.8 (4.67–10.6) 14 7.4 (4.6–27.5) 2 NE
CBR clinical benefit rate (defined as CR ? PR ? stable disease C6 months), CI confidence interval, CR complete response, DOR duration of
response, PFS progression-free survival, NE not estimable, ORR objective response rate, PD progressive disease, PR partial response, TTR time
to response. Disease control rate defined as CR ? PR ? stable disease
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Treatment-related AEs led to dose adjustment (interrup-
tion/delay or reduction) in 28 (50.0 %) patients: 20 patients
(35.7 %) had a dose interruption/delay due to a treatment-
related AE, and 20 patients (35.7 %) underwent dose
reduction due to a treatment-related AE. Neutropenia, leu-
kopenia, and peripheral neuropathy were the most common
TRAEs leading to dose interruption (in 13, 4, and 3 patients,
respectively); dose reductions were most commonly due to
neutropenia and peripheral neuropathy (in 12 and 7 patients,
respectively). None of the dose interruptions or reductions
occurred following use of growth factors. Six patients
(10.7 %) discontinued the study drug due to TRAE.
Peripheral neuropathy was responsible for 5 of the 6 events
resulting in discontinuations; the remaining patient experi-
enced a prolonged QT interval requiring drug withdrawal.
The median time to first occurrence of peripheral neuropathy
(any grade) was 4 months. The median duration of grade 3/4
peripheral neuropathy was 2.3 months (range 0.2–2.5).
Discussion
This phase 2 study evaluated first-line treatment for locally
recurrent breast cancer or MBC with eribulin, which is
approved for use in later lines of treatment. In this population
of women with HER2-negative MBC, first-line eribulin
resulted in a 29 % ORR, with a 52 % CBR and a median PFS
of 6.8 months. These results are comparable to those obtained
with single-agent anthracyclines or taxanes. For example, a
phase 3 study comparing doxorubicin (n = 201) and pegy-
lated liposomal doxorubicin (n = 209) reported ORRs of 38
and 33 %, respectively, with 25 % of patients in each group
having stable disease, and PFS of 7.8 and 6.9 months,
respectively [15]. An analysis of individual patient data from
studies of first-line single-agent anthracycline (doxorubicin)
or taxane therapy (paclitaxel or docetaxel) found ORRs of
38 % with anthracyclines and 33 % with taxanes, with stable
disease rates of 37 and 40 %, respectively, and median PFS of
7.2 and 5.1 months, respectively [16].
Clinical benefit with eribulin was observed in patients
with estrogen receptor-positive or TN MBC status. This
finding is consistent with previous observations, including
results from the EMBRACE trial [12] and another phase 3
trial [14] that showed improved OS with eribulin compared
with other chemotherapy (treatment of physician’s choice
or capecitabine, respectively) among patients with TN
MBC. Similarly, clinical benefit was seen in patients with
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Fig. 3 Waterfall graphs of
percentage change in total sum
of target lesion diameters from
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No prior chemotherapy (n=20)
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treatment, although PFS and DOR were generally longer in
patients whose cancers were A/T-naı¨ve. However, the
small numbers of patients in the subgroups preclude any
definitive conclusions about differences in outcomes.
The tolerability profile of eribulin in this study was
consistent with what has been reported in previous studies
[9–12]; the most common TRAEs of any grade were alo-
pecia, neutropenia, fatigue, and peripheral neuropathy.
Neutropenia was the most common grade 3/4 TRAE and
led to dose modification in 16 of 56 patients, but no dis-
continuations due to neutropenia were reported. However,
neutropenia did not appear to substantially influence effi-
cacy outcomes; among subjects with or without neutrope-
nia grade 3 or lower (n = 28 in each group), the ORR was
8/28 in each group and median PFS was 208 days (with)
compared with 203 days (without).
Neuropathy is an adverse event frequently observed with
agents that target tubulin and can occasionally be severe [17].
For example, rates of grade 3/4 peripheral neuropathy up to
33 % have been reported in studies of patients treated with
taxanes for breast cancer, although the specific incidence can
vary depending on the particular agent, dose per cycle,
cumulative dose, treatment schedule, and duration of infu-
sion [17]. Peripheral neuropathy was reported as treatment-
related in 57 % (32/56) of patients in this study (19.6 %
grade 3/4). This incidence is higher than what has been
observed in other studies of eribulin [12, 14]. This may be
because peripheral neuropathy is a cumulative adverse
event, and so, earlier line eribulin patients who receive more
cycles may be more likely to develop it (for example, the
median duration of exposure in this study was 4.5 months
and median number of cycles was 7, compared with
3.9 months [12] and 5 cycles [Data on file, Eisai Inc.] in the
EMBRACE study); alternatively, it could be due to the fact
that this study has a very small patient population relative to
the previous studies. Peripheral neuropathy was cited as the
reason for dose modification in 10 patients; as only 5 (9 %)
patients discontinued treatment due to peripheral neuropa-
thy, this toxicity was generally manageable with dose
reduction or delay. The median time to first occurrence of
peripheral neuropathy (of any grade) was 4 months (range
0.3–30.9), and the duration of grade 3/4 peripheral neurop-
athy was a median of 2.3 months (range 0.2–2.5) with proper
dose modification. The median-delivered dose intensity of
eribulin was 95 %, indicating that most patients received the
planned dose of 1.4 mg/m2 on Days 1 and 8.
Eribulin offers a shorter administration time relative to
other first-line chemotherapies for MBC; it is administered
as a 2- to 5-min IV infusion and does not require admin-
istration of premedication. Eribulin as first-line treatment
for MBC has antitumor activity comparable with other
established cytotoxic agents with acceptable safety and
tolerability. Eribulin is being explored as part of neo/
adjuvant regimens in ongoing trials; a phase 3 study is
currently underway to evaluate eribulin versus weekly
paclitaxel in 1st/2nd-line MBC.
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